A platform for integrating cell signaling and single cell transcriptomics.

Information

  • Research Project
  • 9847520
  • ApplicationId
    9847520
  • Core Project Number
    R43HG010592
  • Full Project Number
    1R43HG010592-01A1
  • Serial Number
    010592
  • FOA Number
    PA-18-574
  • Sub Project Id
  • Project Start Date
    9/1/2019 - 4 years ago
  • Project End Date
    2/29/2020 - 4 years ago
  • Program Officer Name
    GILCHRIST, DANIEL A
  • Budget Start Date
    9/1/2019 - 4 years ago
  • Budget End Date
    2/29/2020 - 4 years ago
  • Fiscal Year
    2019
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    8/20/2019 - 4 years ago
Organizations

A platform for integrating cell signaling and single cell transcriptomics.

PROJECT SUMMARY Cells communicate through physical interaction of cell surface proteins or through autocrine, paracrine, juxtacrine or endocrine mechanisms. However, cell types identified by current large-scale single-cell sequencing and spatial transcriptomics efforts may mask heterogeneity in functional responses between cell types. Our ultimate vision for a product would be a platform to interrogate multiple cell-types in different combinations and under different biochemical conditions to understand heterogenous gene expression responses. In phase I of this SBIR, Scribe Biosciences will adapt its proprietary Printed Droplet Microfluidics (PDM) technology to study the impact of perturbations on single-cell transcriptomics. PDM can precisely deliver reagents and single cells to a microwell array at any time, enabling flexible multi-step workflows while maintaining high experimental throughputs. PDM will be used to encapsulate single-cells, incubate them either with an agonist/antagonist or additional cell(s) of different cell-types, and perform scRNA-seq to understand induced transcriptional changes. A novel lipid-barcoding scheme will be used to link cells encapsulated in the same droplets, enabling cells to be recovered with traceable signatures in bulk and sequenced by established single- cell methods. In Specific Aim 1 we will demonstrate the ability to perturb and incubate single cells in a test system where single Jurkat cells isolated in droplets are treated with anti-CD3 and anti-CD28 antibodies, then assayed for IL2p expression. In Specific Aim 2 we will demonstrate a barcoding method to bioinformatically link cells incubated within the same droplet while allowing them to be sequenced separately. The successful execution of this phase I program will demonstrate the technical feasibility of a high throughput functional genomics platform using our PDM technology and will set the stage for a numerical scale up of the platform to analyze up to 10,000 single cells.

IC Name
NATIONAL HUMAN GENOME RESEARCH INSTITUTE
  • Activity
    R43
  • Administering IC
    HG
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    350000
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    172
  • Ed Inst. Type
  • Funding ICs
    NHGRI:350000\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SCRIBE BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
    079569722
  • Organization City
    SAN FRANCISCO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    941173371
  • Organization District
    UNITED STATES